ADRIAAN W. DEKKER, M.D.; MAJA ROZENBERG-ARSKA, M.D.; JAN J. SIXMA, M.D.; JAN VERHOEF, M.D.
Fifty-two patients with acute nonlymphocytic leukaemia were studied during remission induction treatment in a randomized trial to ascertain the effect of prophylactic oral trimethoprim-sulfamethoxazole on infection and fever rate. A decrease in the total number of acquired infections was found (16 infections in the group given trimethoprim-sulfamethoxazole versus 31 in the control group, p < 0.01). The number of patients without any infection in the trimethoprim-sulfamethoxazole group was 13 compared to only three in the control group (p < 0.01). Patients in the trimethoprim-sulfamethoxazole group needed parenteral antibiotics during 33% of the days they were granulocytopenic compared to 61% of these days for patients in the control group. However, six of nine bacteriologically documented infections in the trimethoprim-sulfamethoxazole group were caused by resistant microorganisms compared to two out of 20 in the control group.
ADRIAAN W. DEKKER, MAJA ROZENBERG-ARSKA, JAN J. SIXMA, JAN VERHOEF. Prevention of Infection by Trimethoprim-Sulfamethoxazole Plus Amphotericin B in Patients with Acute Nonlymphocytic Leukaemia. Ann Intern Med. 1981;95:555–559. doi: 10.7326/0003-4819-95-5-555
Download citation file:
Published: Ann Intern Med. 1981;95(5):555-559.
Hematology/Oncology, Infectious Disease, Leukemia/Lymphoma.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use